VieCure announced it has raised $43 million to accelerate the rollout of its software platform designed to help community oncology clinics deliver precision-medicine care with greater speed and consistency.
The financing was led by Mitch Rales, the Danaher co-founder, and Northpond Ventures. Durable Capital Partners, Socium Ventures—a venture firm backed by Cox Enterprises—and Sator Grove Holdings also participated.
As part of the round, Rales and Howard “Skip” Burris III, M.D., a past president of the American Society of Clinical Oncology, joined VieCure’s board.
VieCure is positioning the raise around the widening operational gap facing community oncology practices, which treat the vast majority of U.S. cancer patients. The company said these clinics are increasingly strained by the growing complexity of modern cancer care and the expanding set of precision-medicine protocols, creating pressure on both patient outcomes and practice economics.
At the center of VieCure’s offering is Halo Intelligence, which the company describes as an AI-powered clinical decision support system and oncology-focused electronic medical record. VieCure said the platform uses structured patient data, workflow automation, and artificial intelligence to support real-time clinical decisions and reduce operational friction across diagnosis, treatment planning, and follow-up care.
VieCure said it now supports care management for nearly 30,000 patients across a growing national network of practice locations. The company also cited reported performance improvements among participating practices, including an approximately eight-fold increase in tumor sequencing rates, roughly a two-fold increase in guideline-compliant treatment plans, and gains in physician capacity and workflow productivity.
KEY QUOTES:
“This investment marks a pivotal moment in our mission to transform how cancer care is delivered to patients everywhere. Every day, oncologists use our platform to personalize treatment and connect patients to the right therapies at the right time.”
Michael Power, CEO, VieCure
“VieCure is profoundly improving people’s lives, so I’m honored to join the board and…partner with VieCure’s talented management team to instill in VieCure the highest level of operating capabilities…We are committed to VieCure for the long-term.”
Mitch Rales, Co-Founder, Danaher; Board Member, VieCure
“With an intelligent software platform designed for clinical precision and ease of use, VieCure is poised to become the largest conduit for evidence-based, guideline-informed care for cancer patients.”
Michael Rubin, M.D., Ph.D., CFA, Founder and CEO, Northpond Ventures
“VieCure helps practices reduce clinician burden, stay aligned with evolving standards, and focus on delivering timely and appropriate care for every patient.”
Howard A. “Skip” Burris III, M.D., VieCure Board Member; Medical Oncologist; Past President, ASCO
“Halo Intelligence improves coordination across our team, strengthens clinical and diagnostic decision-making, and streamlines operations—it’s become central to how we manage our business and improve the care we deliver.”
Ashvini Sengar, M.D., President and Chief Medical Officer, Alabama Cancer Care
